- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Type 2 Diabetes Mellitus (T2D)
- Meeting Date: July 2023
- Public Summary Document (PSD) July 2023 PBAC Meeting - (PDF 910KB)
- Public Summary Document (PSD) July 2023 PBAC Meeting - (Word 503KB)
Tirzepatide – July 2023
Tirzepatide: Injection 2.5 mg in 0.5 mL pre-filled pen, Injection 5 mg in 0.5 mL pre-filled pen, Injection 7.5 mg in 0.5 mL pre-filled pen, Injection 10 mg in 0.5 mL pre-filled pen, Injection 12.5 mg in 0.5 mL pre-filled pen, Injection 15 mg in 0.5 mL pre-filled pen; Mounjaro® - July 2023
Last updated
10 November 2023
